Barth Syndrome
Symptoms, Doctors, Treatments, Advances & More

Learn About Barth Syndrome

What is the definition of Barth Syndrome?

Barth syndrome is a rare condition characterized by an enlarged and weakened heart (dilated cardiomyopathy), weakness in muscles used for movement (skeletal myopathy), recurrent infections due to small numbers of white blood cells (neutropenia), and short stature. Barth syndrome occurs almost exclusively in males.

What are the causes of Barth Syndrome?

Mutations in the TAFAZZIN gene cause Barth syndrome. The TAFAZZIN gene provides instructions for making a protein called tafazzin. This protein is located in structures called mitochondria, which are the energy-producing centers of cells. The tafazzin protein is involved in altering a fat (lipid) called cardiolipin, which plays critical roles in the mitochondrial inner membrane. Once altered by tafazzin, cardiolipin is key in maintaining mitochondrial shape, energy production, and protein transport within cells.

How prevalent is Barth Syndrome?

Barth syndrome is estimated to affect 1 in 300,000 to 400,000 individuals worldwide. More than 150 cases have been described in the scientific literature.

Is Barth Syndrome an inherited disorder?

This condition is inherited in an X-linked recessive pattern. The gene associated with this condition is located on the X chromosome, which is one of the two sex chromosomes. In males (who have only one X chromosome), one altered copy of the gene in each cell is sufficient to cause the condition. In females (who have two X chromosomes), a mutation would have to occur in both copies of the gene to cause the disorder. Because it is unlikely that females will have two altered copies of this gene, males are affected by X-linked recessive disorders much more frequently than females. A characteristic of X-linked inheritance is that fathers cannot pass X-linked traits to their sons.

Who are the top Barth Syndrome Local Doctors?
Elite in Barth Syndrome
Elite in Barth Syndrome
Referral may be required
Amsterdam, NH, NL 

Frederic Vaz practices practicing medicine in Amsterdam, Netherlands. Mr. Vaz is rated as an Elite expert by MediFind in the treatment of Barth Syndrome. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Barth Syndrome, Primary Carnitine Deficiency, Cerebrotendinous Xanthomatosis, Zellweger Syndrome, and Laryngectomy.

Elite in Barth Syndrome
Elite in Barth Syndrome
Referral may be required
Upper Maudlin St, 
Bristol, ENG, GB 

Colin Steward practices practicing medicine in Bristol, United Kingdom. Mr. Steward is rated as an Elite expert by MediFind in the treatment of Barth Syndrome. He is also highly rated in 7 other conditions, according to our data. His clinical expertise encompasses Barth Syndrome, Delayed Growth, Infantile Neutropenia, Osteopetrosis, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Barth Syndrome
Elite in Barth Syndrome
Referral may be required
501C-715 McDermot Avenue, R3E 3P4, 
Winnipeg, MB, CA 

Grant Hatch practices practicing medicine in Winnipeg, Canada. Mr. Hatch is rated as an Elite expert by MediFind in the treatment of Barth Syndrome. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Barth Syndrome, Sitosterolemia, Gestational Diabetes, and Agranulocytosis.

What are the latest Barth Syndrome Clinical Trials?
Global Mitochondrial Registry to Define Natural History and Outcome Measures to Achieve Definite Trial Readiness for Mitochondrial Disorders

Summary: The main goal of the project is provision of a global registry for mitochondrial disorders to harmonize previous national registries, enable world-wide participation and facilitate natural history studies, definition of outcome measures and conduction of clinical trials.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients With Genetically Confirmed Barth Syndrome

Summary: Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily SC injection of elamipretide in subjects with genetically confirmed BTHS for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States(FORZINITY™) under the accelerated approval b...

Who are the sources who wrote this article ?

Published Date: November 24, 2021
Published By: National Institutes of Health